Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. filed an 8-K with the Securities and Exchange Commission on June 30, 2020, under the ticker LACQ. The special purpose acquisition company was active in the healthcare and biopharmaceutical sector, focused on pharmaceutical development targeting abuse-deterrent drug formulations. The June 2020 filing represented a material event disclosure during the SPAC's operational lifecycle, consistent with standard reporting obligations for blank-check companies advancing toward a business combination. As with many healthcare-focused SPACs of that vintage, the filing reflects a period of heightened SPAC activity across the life sciences space. Sign up at SpacDesk for full filing history, sponsor data, and deal status on LACQ and every other SPAC in our database.